Noble Capital initiated coverage of Zomedica (ZOM) with an Outperform rating and 25c price target The company makes and sells veterinary therapeutic devices and diagnostics used to diagnose and treat animals ranging from horses to cats, dogs, and other pets, the analyst tells investors. Zomedica has grown by acquiring complementary businesses that broaden its product line and leverage its existing infrastructure, notes the firm, which values the stock based on its estimate of the company’s FY27 revenues.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZOM: